PMID: 9555597Apr 29, 1998Paper

A controlled trial of ondansetron, a 5-HT3 antagonist, in benzodiazepine discontinuation

Journal of Clinical Psychopharmacology
M K RomachE M Sellers

Abstract

Serotonin is implicated in the etiology of anxiety disorders and in the anxiolytic actions of benzodiazepines. Preclinical studies with 5-HT3 receptor antagonists, including ondansetron, show they have anxiolytic properties and that ondansetron suppresses withdrawal anxiety after abrupt discontinuation of chronic benzodiazepine treatment. We evaluated the efficacy of ondansetron as an adjunctive medication in the discontinuation of benzodiazepines in long-term users. One hundred eight patients who had used alprazolam or lorazepam regularly for > 3 months entered, and 97 completed a randomized double-blind discontinuation treatment program during which they received either ondansetron 2 mg twice daily or placebo and flexibly tapered their benzodiazepine over a 6-week period. There were no significant differences between the patients who had entered and completed treatment. Three weeks postmedication, 63% of the patients discontinued use of benzodiazepine. The percentage of reduction of benzodiazepine daily dosage at all time points in the treatment trial was similar for the ondansetron and placebo groups. Ondansetron had no significant effects on severity of withdrawal symptoms or levels of anxiety. High placebo response may hav...Continue Reading

References

Apr 1, 1979·The British Journal of Psychiatry : the Journal of Mental Science·S A Montgomery, M Asberg
Mar 1, 1992·Pharmacology & Toxicology·B Costall, R J Naylor
Oct 1, 1992·Clinical Pharmacology and Therapeutics·A L Suchman, R Ader
Oct 1, 1992·Journal of Clinical Psychopharmacology·M K RomachE M Sellers
Oct 1, 1992·Journal of Clinical Psychopharmacology·R L DuPontJ C Pecknold
Sep 1, 1992·Archives of General Psychiatry·J W NewcomerJ G Csernansky
Mar 1, 1990·The British Journal of Psychiatry : the Journal of Mental Science·T CantopherJ G Edwards
Aug 28, 1990·European Journal of Pharmacology·A J Goudie, M J Leathley
May 1, 1990·Pharmacology, Biochemistry, and Behavior·M P Johnson, D E Nichols
Jun 1, 1990·Pharmacology, Biochemistry, and Behavior·B CostallM B Tyers
Jan 1, 1990·Pharmacology & Therapeutics·B CostallM B Tyers
Oct 1, 1990·Archives of General Psychiatry·K RickelsD J Greenblatt
Oct 1, 1990·Archives of General Psychiatry·E SchweizerD J Greenblatt
Dec 1, 1989·Journal of Clinical Psychopharmacology·U E BustoE M Sellers
Dec 1, 1989·Pharmacology, Biochemistry, and Behavior·B CostallM B Tyers
Jan 1, 1985·Neuroscience and Biobehavioral Reviews·D Treit
Mar 13, 1986·The New England Journal of Medicine·E SchweizerI Lucki
Dec 1, 1986·The American Journal of Psychiatry·E Schweizer, K Rickels
Feb 1, 1987·Journal of Clinical Psychopharmacology·M Lader, D Olajide
Apr 1, 1988·British Journal of Pharmacology·B J JonesM B Tyers
Apr 1, 1989·Annals of Internal Medicine·J R WoodsM Tavel
Apr 1, 1989·The American Journal of Psychiatry·R K RiesS Cullison
Jan 15, 1988·Biological Psychiatry·R S KahnG Barr
Jan 1, 1974·Behavioral Science·L R DerogatisL Covi
Mar 7, 1981·Lancet·P TyrerT Huggett
Aug 1, 1995·The American Journal of Psychiatry·M RomachE Sellers
Aug 1, 1994·Alcoholism, Clinical and Experimental Research·E M SellersM B Sobell
Jun 1, 1994·The American Journal of Psychiatry·David Spiegel

❮ Previous
Next ❯

Citations

Nov 20, 2002·Biological Psychiatry·Justine M KentJack M Gorman
Feb 26, 2003·European Journal of Pharmacology·Sandra E File, Pallab Seth
Mar 9, 2000·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·B OlivierW Soudijn
Dec 14, 2011·Current Opinion in Psychiatry·Jozsef Haller, Mano Alicki
Dec 10, 2008·CNS Drugs·Malcolm LaderJohn Donoghue
Jul 5, 2015·BMC Pharmacology & Toxicology·André S PollmannDavid M Gardner
Sep 18, 2012·Neuroscience and Biobehavioral Reviews·J HallerK Gyimesine Pelczer
Jul 9, 2004·Addictive Behaviors·Anne-Déborah BouhnikUNKNOWN MANIF 2000 Study Group
Aug 19, 2008·Drug and Alcohol Dependence·Silvia S MartinsHoward D Chilcoat
Jan 17, 2004·Drug and Alcohol Dependence·Bruna BrandsUsoa Busto
Feb 4, 2010·Journal of Psychopharmacology·Ramamoorthy Rajkumar, Radhakrishnan Mahesh
Mar 16, 2018·The Cochrane Database of Systematic Reviews·Lone BaandrupBirte Y Glenthøj
Dec 10, 1999·Journal of Clinical Psychopharmacology·K RickelsL Mandos
Mar 3, 2020·Medicinal Research Reviews·Radomir JuzaJan Korabecny
Jun 20, 2013·The Cochrane Database of Systematic Reviews·Cecile DenisMarc Auriacombe
Aug 18, 2018·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Emily R SternWayne K Goodman
May 2, 2018·Therapeutic Advances in Psychopharmacology·Dimy FluyauBrittany E Manobianco
May 11, 2020·Sleep Medicine Clinics·Jonathan P Hintze, Jack D Edinger

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.